Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708916 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
A Phase 1 study of Discoid Lupus Erythematosus, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00708916 is a Phase 1 study of Discoid Lupus Erythematosus that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00708916, a Phase 1 study of Discoid Lupus Erythematosus, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
Conditions Studied
Interventions
- DRUG CC-10004
Study Locations (1)
New York
- New York University Tisch Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708916
The ClinicalTrials.gov registry entry for NCT00708916 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Discoid Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which CC-10004 is the first listed.
NCT00708916 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00708916 about?
NCT00708916 is a clinical study titled "Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients". The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
What is the current status of trial NCT00708916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-06. Estimated completion is 2010-08.
What conditions does trial NCT00708916 study?
This clinical trial studies the following conditions: Discoid Lupus Erythematosus.
What interventions are being tested in trial NCT00708916?
The interventions under investigation include: CC-10004 (DRUG).
Who is sponsoring clinical trial NCT00708916?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00708916 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.